Maternal-Fetal Medicine

Maternal-Fetal Medicine is a quarterly open-access journal founded in 2019 by the Chinese Medical Association and co-published with Wolters Kluwer, carrying clinical and translational work on the pregnant woman, the fetus and the exchanges between them, and its 2025 Journal Impact Factor is 1.9.《母胎医学杂志》由中华医学会于 2019 年创办，与 Wolters Kluwer 联合出版，以开放获取形式按季发行，刊载母体医学与胎儿医学的临床及转化研究，2025 年期刊影响因子为 1.9。

Scope

• The stated aim is to publish high quality work across obstetrics and maternal-fetal medicine, from original clinical and translational research to state-of-the-art reviews, commentaries, case studies and letters.刊物声明的宗旨是刊发产科与母胎医学各方向的高水平成果，从原创临床与转化研究到前沿综述，述评，病例分析与读者来信。

• Medical complications of pregnancy head the list of covered areas, so hypertensive disease, gestational diabetes, thyroid disorders and cardiac conditions in gestation all sit inside the remit.妊娠期内科合并症居于收录方向之首，妊娠期高血压，妊娠期糖尿病，甲状腺疾病与心脏病都属选稿范围。

• Adverse outcomes of pregnancy form a second strand, taking in preterm birth, preterm rupture of membranes, miscarriage and the events that cut a pregnancy short.妊娠不良结局构成第二条主线，涵盖早产，未足月胎膜早破，流产以及其他使妊娠提前终止的事件。

• Fetal development and growth are followed from early organogenesis to term, and growth restriction or macrosomia is handled as a clinical problem that decides the timing of delivery.胎儿发育与生长从早期器官形成一直追踪到足月，胎儿生长受限或巨大儿按决定分娩时机的临床问题处理。

• Prenatal screening and diagnosis draw ultrasound, maternal serum markers, cell-free DNA and invasive sampling into a single workflow, and work on the accuracy of each step belongs here.产前筛查与诊断把超声，母血清标志物，游离 DNA 与侵入性取样串成一条流程，评估各环节准确性的研究由此进入刊物。

• Fetal treatment and therapy appear through intrauterine transfusion, laser photocoagulation for twin-twin transfusion, shunting and open or fetoscopic repair of selected anomalies.胎儿治疗经由宫内输血，双胎输血综合征的激光凝固，分流术以及针对特定畸形的开放式或胎儿镜修补呈现。

• Technology and developments in the field are treated as a standing category, covering telemedicine, obstetric early warning scores, decision support and the sensors that feed them.学科技术与进展单列一类，覆盖远程医疗，产科早期预警评分，决策支持以及为这些系统采集数据的传感器。

• Placental disease receives steady attention, from placenta previa and the accreta spectrum to the vascular lesions that leave a fetus undernourished.胎盘疾病持续受到关注，从前置胎盘与植入谱系到使胎儿营养供给不足的血管病变。

• Severe maternal morbidity and obstetric critical care stand as a subject of their own, including postpartum haemorrhage, sepsis and the organisation of maternal intensive care.严重母体并发症与产科重症自成一类选题，涉及产后出血，脓毒症以及母体重症监护的组织方式。

• Pregnancy in women with pre-existing disease is handled together with internists, which brings lupus, chronic kidney disease and intrahepatic cholestasis of pregnancy into the pages.合并基础疾病的妊娠常与内科共同处理，红斑狼疮，慢性肾病与妊娠期肝内胆汁淤积症因此进入版面。

• Genetics and rare disease enter through carrier screening, exome sequencing of anomalous fetuses and the counselling that follows a molecular result.遗传学与罕见病经由携带者筛查，异常胎儿的全外显子测序以及分子诊断之后的遗传咨询进入刊物。

• Imaging and fetal monitoring cover Doppler studies, magnetic resonance, cardiotocography and the interpretation rules that turn a tracing into a decision.影像与胎儿监护涵盖多普勒检查，磁共振，胎心监护以及把一条曲线转成临床决策的判读规则。

• Perinatal epidemiology and birth cohorts supply the population frame, so registry analyses and long-term follow-up of children are published alongside trials.围产流行病学与出生队列提供人群层面的证据，登记数据分析与儿童长期随访因此与临床试验同列。

• Guidelines, expert consensus and quality improvement reports have a regular place, many of them drafted by Chinese colleges and issued in English for wider use.指南，专家共识与质量改进报告有固定位置，其中不少由中国专家组起草并以英文发表，供更广范围使用。

• Case reports and correspondence are kept for findings that teach something a full study cannot, and short educational perspectives appear in most issues.病例报告与通信留给完整研究难以承载的教学性发现，篇幅短小的教育类述评几乎每期都有。

History

• The first issue appeared in July 2019, and the title was the first English-language journal in maternal-fetal medicine to come out of China.首期于 2019 年 7 月问世，这是中国母胎医学领域的第一本英文期刊。

• By then maternal-fetal medicine had become a specialty in its own right in the country, with tertiary referral centres, fetal surgery programmes and large birth cohorts, yet no domestic journal reached readers abroad.那时的中国母胎医学已成独立专科，三级转诊中心，胎儿手术项目与大型出生队列相继建立，却没有一份本土刊物进入海外读者的视野。

• Support came from the China Association for Science and Technology, whose journal programmes backed the launch and a later round of capacity building.中国科学技术协会的期刊项目为创刊提供了支持，其后又有一轮出版能力建设资助跟进。

• Publication was arranged with Wolters Kluwer from the outset, so the journal went out in print and online on the Lippincott platform at the same time.出版事务自始与 Wolters Kluwer 合作，刊物同时以纸质与网络形式在 Lippincott 平台发行。

• The editorial office sits with the Chinese Medical Association Publishing House in Beijing, and the first board joined mainland obstetricians with overseas Chinese and international advisers.编辑部设在北京的中华医学杂志社，首届编委会由内地产科医师与海外华人学者，国际顾问共同组成。

• Within China the title is registered under the domestic serial number CN 10-1632/R, which identifies it as an officially published Chinese periodical with a Chinese-language name of its own.该刊在国内以《母胎医学杂志（英文）》登记，国内统一连续出版物号为 CN 10-1632/R，这一注册身份确认它是正式出版的中国期刊。

• Four issues a year were planned from volume one and the rhythm has held, with each issue in 2025 and 2026 carrying a dozen or so papers.季刊形制自第一卷即已定下并沿用至今，2025 年与 2026 年的每一期都刊出十余篇论文。

• PubMed and PubMed Central began indexing with volume 4, issue 1, in 2022, three years after launch, which put the early volumes within reach of clinicians abroad.PubMed 与 PubMed Central 从 2022 年第四卷第一期起收录，距创刊三年，早期卷册由此进入海外临床医生的检索范围。

• Clarivate then added the journal to the Emerging Sources Citation Index, and the first Journal Impact Factor, 1.2, was released in 2023.Clarivate 随后将该刊纳入 Emerging Sources Citation Index，首个期刊影响因子 1.2 于 2023 年发布。

• The figure rose to 1.7 in 2024 and 1.9 in 2025, while the five-year impact factor settled at 1.7 and the Journal Citation Indicator reached 0.48.该数值在 2024 年升至 1.7，2025 年为 1.9，五年影响因子停在 1.7，期刊引文指标达到 0.48。

• In the 2025 release it holds a third quartile position in obstetrics and gynecology, at 84 of 143 titles on the ESCI list.2025 年版报告中该刊列妇产科学第三四分位，在 ESCI 名单的 143 种刊物中排第 84 位。

• About 300 citations accrued in the reporting window, the cited half-life is 3.4 years and the annual article count near 15, figures that trace a young journal's citation curve.报告期内累计被引约 300 次，引用半衰期 3.4 年，年发文量约 15 篇，这些数字描出一本新刊的被引曲线。

• Open access was the model from the first volume, articles carry a CC BY-NC-ND licence, and no article processing charge is levied on authors.开放获取自第一卷即为既定模式，论文采用 CC BY-NC-ND 许可，作者不需缴纳文章处理费。

• Output has widened since 2023, with more than fifty papers deposited in each of 2025 and 2026, and the seventh volume closed in 2025.2023 年以来刊文量逐步扩大，2025 年与 2026 年各自登记的论文均超过 50 篇，第七卷在 2025 年出齐。

• Listings in DOAJ and adherence to the Budapest open access declaration fixed the licence terms and the no-fee policy in a public record.收录于 DOAJ 并遵循布达佩斯开放获取宣言，许可条款与免费政策因此留下公开记录。

Editors

• Two editors-in-chief share the post, Huixia Yang of Peking University First Hospital and Guoyang Luo, and Gian Carlo Di Renzo, a former secretary general of FIGO, serves as honorary editor-in-chief.主编一职由两人共同担任，分别是北京大学第一医院的 Huixia Yang 与 Guoyang Luo，国际妇产科联盟前秘书长 Gian Carlo Di Renzo 任名誉主编。

• His FIGO years give the board a working route into international obstetric bodies, which is what an honorary editorship is for at a title still building its readership.他在国际妇产科联盟的任职经历为编委会打通了与国际产科组织的往来渠道，这也是新刊保留名誉主编一职的用意。

• The editorial board numbered 53 members from 18 countries as of 2025, a group weighted toward China but with standing representation in Europe and North America.截至 2025 年，编委会由来自 18 个国家的 53 位专家组成，成员以中国学者为主，欧洲与北美也有固定席位。

• Members come from obstetrics, fetal medicine and imaging, medical genetics and neonatology, so a paper on fetal therapy can be read by people who perform the procedure.编委来自产科，胎儿医学与影像，医学遗传学以及新生儿科，胎儿治疗类稿件因此能由实际开展该技术的同行审读。

• Review is double anonymous, with author and referee identities withheld from each other, a model the journal reports to DOAJ in its public record.评审采用双盲方式，作者与审稿人彼此匿名，这一模式在该刊向 DOAJ 提交的公开记录中列明。

• Manuscripts enter through Editorial Manager on the Ovid platform, and the editorial office screens each one for scope, ethics approval and duplicate publication before review.稿件经 Ovid 平台的 Editorial Manager 系统提交，编辑部先核查选题范围，伦理批件与重复发表，再送出评审。

• Similarity checking runs on every submission, and the legal and ethical policies, including trial registration and consent requirements, are published on a dedicated page.每篇投稿都做相似度检测，法律与伦理政策另设专页公布，涉及临床试验注册与知情同意的要求。

• Every article carries a DOI under the 10.1097/FM9 stem, a prefix segment that sets the title apart from the rest of the Lippincott medical list.每篇论文的 DOI 都挂在 10.1097/FM9 词干下，这一前缀段把本刊与 Lippincott 医学刊群中的其他刊物区分开来。

• Original articles, reviews, guideline and consensus statements, case reports, perspectives and correspondence each carry a stated format and length in the instructions to authors.原创论著，综述，指南与共识，病例报告，视角评论与通信各有规定的体例与篇幅，作者须知逐项说明。

• No submission fee and no processing charge apply, and the board treats that policy as part of its remit to bring Chinese obstetric work to a wider readership.投稿与处理均不收费，编委会把这一政策看作让中国产科成果走向更广读者的职责所在。

• Guideline papers often originate with Chinese expert panels and are edited for international phrasing before they go out for review.指南类稿件多来自中国的专家组，送审之前会按国际表述习惯做编辑处理。

• Themed issues are assembled by guest editors who commission part of the content, while unsolicited papers keep to the ordinary track.专题辑由客座编辑组织，部分稿件为约稿，自由投稿仍走常规流程。